| Revision as of 13:23, 16 December 2011 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm Disambig Humanize, replaced: humanized monoclonal antibody → humanized monoclonal antibody using AWB← Previous edit |
Latest revision as of 23:49, 5 April 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers171,086 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| (10 intermediate revisions by 8 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 450332165 |
|
| verifiedrevid = 470620672 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = '']'' ] II B subunit |
|
| target = '']'' ] II B subunit |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 21: |
Line 21: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 28: |
Line 27: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
|
| CAS_number = 502496-16-4 |
|
| CAS_number = 502496-16-4 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 232D35B3NT |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 38: |
Line 38: |
|
| DrugBank = |
|
| DrugBank = |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
|
|
| molecular_weight = 144.6 ] |
|
|
}} |
|
}} |
|
|
|
|
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>, ''World Health Organization''.</ref><ref>{{cite journal|year=2009|last1=López|first1=EL|last2=Contrini|first2=MM|last3=Glatstein|first3=E|last4=González Ayala|first4=S|last5=Santoro|first5=R|last6=Allende|first6=D|last7=Ezcurra|first7=G|last8=Teplitz|first8=E|last9=Koyama|first9=T|title=Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients.|doi=10.1128/AAC.00343-09|journal=Antimicrobial agents and chemotherapy|pmid=19822704|volume=54|pages=239–243|issue=1|pmc=2798559}}</ref> |
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>{{cite web | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN.pdf | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | publisher = World Health Organization }}</ref><ref>{{cite journal | vauthors = López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S | display-authors = 6 | title = Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli | journal = Antimicrobial Agents and Chemotherapy | volume = 54 | issue = 1 | pages = 239–43 | date = January 2010 | pmid = 19822704 | pmc = 2798559 | doi = 10.1128/AAC.00343-09 }}</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
|
{{reflist}} |
|
<references/> |
|
|
|
|
|
|
{{Monoclonals for infectious disease and toxins}} |
|
{{Monoclonals for infectious disease and toxins}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
{{antiinfective-drug-stub}} |
